Program Monitoring
7,058
Number of Clinics
56,230
Number of Settlements
5,024,214
Enrollments
21,072,838
Disbursements
Bauchi
1,109
9,603
709,137
3,025,430
Gombe
519
5,212
323,372
1,369,468
Jigawa
785
7,536
906,884
4,153,067
Kaduna
276
2,178
206,299
782,889
Kano
1,260
11,840
982,743
3,879,499
Katsina
1,298
6,759
1,065,271
4,803,807
Kebbi
541
2,978
223,452
841,377
Niger
458
3,051
43,773
66,339
Sokoto
380
2,906
202,473
771,341
Yobe
160
1,836
42,251
70,166
Zamfara
272
2,331
318,559
1,309,455
Vaccination Rate
95.76%
Penta 1
91.35%
Penta 2
88.4%
Penta 3
85.91%
Measles
Bauchi
95.58%
91.54%
88.77%
85.84%
Gombe
96.39%
92.93%
90.35%
87.49%
Jigawa
95.91%
92.54%
90.45%
87.79%
Kaduna
95.77%
90.88%
87.36%
83.39%
Kano
95.16%
91.19%
88.32%
85.23%
Katsina
96.41%
92.82%
90.51%
88.42%
Kebbi
95.18%
88.8%
84.49%
82.41%
Niger
94.27%
85.93%
78.82%
85.14%
Sokoto
94.29%
84.16%
78.01%
74.33%
Yobe
95.58%
90.52%
85.83%
90.7%
Zamfara
96.38%
88.82%
83.89%
83.47%
Impact Evaluation Key Findings
An independent randomized controlled trial found, among other positive findings, that New Incentives’ All Babies program:
Increased Coverage
The program doubled the percentage of infants who were fully vaccinated, increasing coverage from roughly a quarter to just over half of all infants.
Improved Timeliness
Infants who received measles vaccines were 33 percentage points more likely to receive the vaccine within one month of the recommended age.
Improved Knowledge and Attitudes
Caregivers in areas served by the program had better knowledge and more favorable attitudes toward immunization.
Reduced Stockouts
Government clinics with the program were 18 percentage points less likely to report vaccine stockouts during the last 12 months.
Randomized Controlled Trial
Expected in Dec 2020
Study with two-arm cluster RCT
- Control (83 clinics): No intervention, status quo
- Treatment (84 clinics): New Incentives full program
- This design will measure the causal effect of New Incentives' program on the likelihood of an infant receiving a vaccine.
.svg)
.svg)
.png)